Neostem Inc. : NeoStem’s CEO Robin Smith Gives ‘The Stock Radio’ an Update on the Company10/04/2012 | 04:57pm US/Eastern
NeoStem's CEO Robin Smith Gives 'The Stock Radio' an Update on the Company Oct 4 2012
New York, October 4, 2012 -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), an emerging leader in the fast growing cell therapy market, gives an update on the Company's progress from the 'NIBA' convention recently held in New York City:http://thestockradio.com/robin-smith-ceo-of-neostem-inc-amexnbs/1538 .
In summary, NeoStem listed on the NYSE MKT, is emerging as a leading cell therapy company that:
Has an Exciting Proprietary Cell Therapy Pipeline
• Phase 2 AMR-001 PreSERVE trial enrollment completion and data read-out expected in 2013
o Patient accrual is underway
o Strong IP portfolio in a rapidly growing industry
o $50 billion is spent annually on regenerative medicine
o Industry projected to increase 15% annually (compounded)
Generates Revenue from Contract Development and Manufacturing Business
• Revenue side of the business averaging >$10 million annually
• Validation of approach through agreements with "Who's Who" of cell therapy companies
Has a Leadership That Can Execute
• Strong management team with decades of regulatory experience
• Successfully completed five M&A transactions
• Obtained $3 million in DOD and NIH funding to advance cell therapy products
• Submitted an additional $13 million in grant applications
Has a Known Presence and Strong Performance on the Street
• Consistent liquidity and strong technical indicators
• Returns of ~24% since July, outperforming the NASDAQ (+5.3%) and S&P 500 (+5.7%) averages
• Respected analyst coverage: Cowen, JMP and WBB
About NeoStem, Inc.
NeoStem, Inc. continues to develop and build on its core capabilities in cell therapy, capitalizing on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy market. Our multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC ("PCT"), with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities. We believe this expertise and existing research capabilities and collaborations will enable us to achieve our mission of becoming a premier cell therapy company.
Our contract development and manufacturing service business supports the development of proprietary cell therapy products. NeoStem's most clinically advanced therapeutic, AMR-001, is being developed at Amorcyte, LLC ("Amorcyte"), which we acquired in October 2011. Amorcyte is developing a cell therapy for the treatment of cardiovascular disease and is enrolling patients in a Phase 2 trial to investigate AMR-001's efficacy in preserving heart function after a heart attack. Athelos Corporation ("Athelos"), which is approximately 80%-owned by our subsidiary, PCT, is collaborating with Becton-Dickinson in the early clinical exploration of a T-cell therapy for autoimmune conditions. In addition, pre-clinical assets include our VSELTM Technology platform as well as our mesenchymal stem cell product candidate for regenerative medicine. Our service business and pipeline of proprietary cell therapy products work in concert, giving us a competitive advantage that we believe is unique to the biotechnology and pharmaceutical industries. Supported by an experienced scientific and business management team and a substantial intellectual property estate, we believe we are well positioned to succeed.
For more information on NeoStem, please visit www.neostem.com.
SOURCE:
finance.yahoo.com
|
